Key result
Candesartan cilexetil once daily reduced mean arterial pressure by 8 mmHg compared to placebo without compromising cardiac performance.
Why the study?
Does candesartan cilexetil improve systemic and forearm haemodynamics in patients with essential hypertension?
RCT (n=22)
Double-blind
crossover
Does candesartan cilexetil improve systemic and forearm haemodynamics in patients with essential hypertension?
Six weeks of treatment with candesartan cilexetil 16 mg daily induced systemic and forearm vasodilatation and reduced blood pressure without compromising cardiac performance.
Answers are grounded in this paper and cite their sources.
Supports candesartan 16 mg daily for BP reduction in essential hypertension without cardiac compromise; extends haemodynamic evidence for AT1-receptor blockade.
The effects of the angiotensin II receptor blocker candesartan cilexetil on systemic and forearm haemodynamics and baroreceptor sensitivity were evaluated in this randomized, placebo-controlled, double-blind, crossover study. After a 4-week placebo run-in period, 22 patients with essential hypertension (diastolic blood pressure 100-114 mmHg) were randomized to receive either candesartan cilexetil 16 mg or placebo once daily for 6 weeks. At the end of each period, 24 h after the last dose, invasive haemodynamic assessments were performed. Simultaneously, the plasma renin activity and plasma concentrations of angiotensin II, aldosterone and catecholamines were measured. Compared to placebo, candesartan cilexetil significantly reduced mean arterial pressure by 8 mmHg (95% CI: 2.6; 12.3), while cardiac output, stroke volume and heart rate were unchanged. Forearm vascular resistance was reduced by 1 mmHg x ml(-1) x L x min (CI: 0.3; 2.3). The baroreceptor sensitivity was not influenced, but a change in the set-point was noted. Plasma renin activity and angiotensin II concentrations were increased, while the aldosterone concentration was significantly reduced. Plasma catecholamine concentrations were unaffected. In conclusion, 6 weeks' treatment with candesartan cilexetil 16 mg o.d. induced systemic and forearm vasodilatation and a reduction in blood pressure without compromising cardiac performance. The plasma concentration of aldosterone was reduced.
No takes yet. Share an insight, caveat, or question.
Moshe Fridman (1999) conducted an RCT in essential hypertension (n=22). candesartan cilexetil vs. placebo was evaluated on mean arterial pressure (MD 8 mmHg reduction, 95% CI 2.6-12.3). Candesartan cilexetil once daily reduced mean arterial pressure by 8 mmHg compared to placebo without compromising cardiac performance.
Synapse has enriched 10 related papers. Consider them for comparative context: